Pathological fracture as a manifestation of extramedullary blastic crisis in chronic myelogenous leukemia: report of one case.
A three-year-old girl with chronic myelogenous leukemia (CML) experienced a pathological fracture of her femur after a demonstrated osteolytic bone lesion. Extramedullary disease (EMD) was diagnosed following the histologic findings of a biopsy of the osteolytic lesion. Frank blast crisis in the bone marrow followed one month later. This was the youngest patient to have been reported in English literature of Philadelphia chromosome positive (Ph+) CML with isolated bony EMD and pathological fracture. Treatment with a tyrosine kinase inhibitor, imatinib mesylate (Gleevec), in bone marrow accelerated phase of CML was failed to reverse the progression of blastic transformation, neither in the extramedullary bone lesion nor in the bone marrow.
Yu
Hsin-Hui
HH
Department of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan.
Lu
Meng-Yao
MY
Lin
Dong-Tsamn
DT
Lin
Kai-Hsin
KH
Tang
Jih-Luh
JL
Jou
Shiann-Tarng
ST
D001549:Benzamides; D001752:Blast Crisis / Q000150:complications* / Q000188:drug therapy; D002675:Child, Preschool; D005260:Female; D005264:Femoral Fractures / Q000209:etiology*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate